Details for Patent: 9,987,274
Which drugs does patent 9,987,274 protect, and when does it expire?
Patent 9,987,274 protects VEOZAH and is included in one NDA.
This patent has thirty-five patent family members in twenty-six countries.
Summary for Patent: 9,987,274
| Title: | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | A method for treating and/or preventing hot flashes, by administering, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Ogeda SA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US15/371,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 9,987,274: Scope, Claims, Expiration and Patent Landscape for Hot-Flash TreatmentsU.S. Patent No. 9,987,274 is a Bayer patent directed to methods of treating or preventing hot flashes with substituted triazolopyrazine compounds, including the clinical candidate elinzanetant. The patent is primarily a method-of-use asset, not a conventional composition-of-matter patent. Its strongest protection is claim 13, which identifies a specific R-enantiomer. Claims 1 and 14 cover broader chemical genera through Markush definitions. The patent issued June 5, 2018. Its nominal patent-term expiration is tied to the earliest effective nonprovisional filing date and is expected to fall in 2034, subject to patent-term adjustment and any future patent-term extension. Because elinzanetant was not FDA-approved in the cited public regulatory record, the patent has no current Orange Book exclusivity or Paragraph IV litigation tied to an approved product. What does U.S. Patent 9,987,274 protect?The patent protects administering defined substituted triazolopyrazine compounds to treat or prevent hot flashes. The protected clinical settings include:
The patent does not claim every NK1 or NK3 antagonist. It requires a compound within the specific Formula I structural framework and administration for the defined hot-flash indication. Core patent information
Source: U.S. Patent No. 9,987,274 [1]. How broad are claims 1 and 14?Claims 1 and 14 are the principal genus claims. They cover a large set of substituted heterocyclic compounds sharing a triazolo[4,3-a]pyrazine core linked to a substituted aryl carbonyl group and a 1,2,4-thiadiazole or 1,2,4-oxadiazole substituent. Claim 1 permits:
Claim 14 uses a similar scaffold but expands R5 to include:
The two independent claims therefore divide the chemical space into two related Markush genera. Claim 14 is especially relevant to oxadiazole and thiadiazole analogues bearing fluorinated ethyl substituents. Estimated combinatorial scopeA simple substituent-count calculation produces a theoretical space of approximately 14,000 combinations for claim 1 and approximately 6,000 combinations for claim 14 before accounting for chemical feasibility, stereochemical restrictions, ring-bond requirements and dependencies among the variables. The legally relevant scope is narrower than this mathematical count because each candidate must satisfy the complete scaffold and bond-definition limitations. The broadest practical risk is therefore not that every enumerated combination will be commercially relevant. It is that a competing product containing a structurally close analogue could fall within the genus even if it is not expressly named in the claims. Which claims provide the strongest protection?Claim 13 is the most commercially significant claim because it identifies a single R-enantiomer: “(R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone.” This claim has substantially less structural breadth than claim 1, but it offers clearer infringement analysis. If the commercial drug is this exact stereochemical compound, claim 13 can provide direct species-level method-of-use coverage. The claims can be ranked by practical enforcement value as follows:
Claims 2, 3, 4, 17, 18 and 19 are dependent use limitations. They narrow the patient population or etiology but do not broaden the underlying chemical scope. What compounds are covered by claim 13?Claim 13 covers the R-enantiomer of the compound containing:
This compound is the most important molecule in the supplied claims because it is separately claimed rather than appearing only as one member of a Markush group. Claim 13 does not, on its face, cover:
A generic or follow-on sponsor could therefore seek to design around claim 13 by changing the heteroaryl ring, stereochemistry, aryl substitution pattern or side-chain substituents. Such a design would still need to be tested against claims 1, 11, 12 and other related patent families. How do the dependent claims narrow the patent?The dependent claims create multiple fallback positions. Patient and treatment limitationsClaims 2 and 17 limit the treatment to hot flashes associated with perimenopause, menopause or postmenopause. Claims 3 and 18 address hot flashes caused by hormone therapy that intentionally reduces sex-hormone levels. Claims 4 and 19 specify therapy-induced hot flashes in cancer patients. These limitations have commercial value because they correspond to the principal clinical use cases for nonhormonal hot-flash treatments. They also create narrower positions if a court limits the broader indication language in claims 1 or 14. Formula subgeneraClaims 5 through 10 and claim 15 depend on structural formulas that were not reproduced in the supplied text. Their legal significance is clear from the claim architecture: they narrow the broad genus to selected combinations of substituents and heteroatom arrangements. Exact infringement mapping requires the missing Formula Ia, Ia-1, Ia-2, Ia-3, Ib and Ic drawings. Compound listsClaims 11, 12 and 16 list specific compounds. These claims may be more difficult to attack on written-description grounds because the patent expressly identifies the covered molecules. Their narrower scope may also make them more valuable as litigation fallback claims. When does U.S. Patent 9,987,274 lose exclusivity?The patent does not expire 20 years after its issue date. U.S. patent term generally runs 20 years from the earliest effective nonprovisional application filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.
An exact expiry date should not be treated as the issue date plus 20 years. The relevant calculation requires the complete priority chain and the USPTO-reported patent-term adjustment. What is the Orange Book status of U.S. Patent 9,987,274?The patent is not currently associated with an FDA-approved product in the cited regulatory record. As a result, it does not presently create Orange Book-based approval delay for an ANDA applicant. If the claimed compound later receives FDA approval, the patent holder could seek listing if the patent meets FDA’s listing standards and claims an approved drug substance, drug product or method of use. A method-of-use patent is most likely to be relevant if the approved labeling includes the hot-flash indications recited in the claims. Orange Book listing would matter because an ANDA applicant could then submit a Paragraph IV certification asserting that the listed patent is invalid, unenforceable or not infringed. Without an approved reference listed drug and a corresponding ANDA pathway, Paragraph IV risk is not presently operative. Are there Paragraph IV challenges or patent litigation?No Paragraph IV challenge is identified for U.S. Patent 9,987,274 in the cited record. The absence of a challenge is consistent with the lack of an FDA-approved reference product based on the claimed compound. No patent litigation involving this patent is identified in the supplied materials. The most likely future dispute triggers would be:
For a method-of-use patent, induced-infringement analysis would likely focus on product labeling, promotional materials, clinical-use instructions and the extent to which the manufacturer encourages treatment of the claimed hot-flash conditions. What generic entry risks exist?Generic entry risk is currently low in practical terms because the claimed product was not identified as an FDA-approved reference product in the cited record. After approval, risk would depend on the commercial product’s active ingredient, stereochemistry, labeling and Orange Book listings. Potential launch scenarios
A skinny-label strategy could be commercially relevant because the patent claims use of the compound for hot flashes rather than all therapeutic uses. Its effectiveness would depend on the approved label and actual prescribing behavior. What formulation and manufacturing protection exists?The supplied claims do not cover:
This distinction is important. U.S. Patent 9,987,274 may block use of a covered compound for hot flashes, but it does not independently establish protection for every formulation or manufacturing route. Commercial exclusivity would likely depend on a broader patent family, including composition-of-matter, process, formulation, salt, crystal-form or additional method-of-use patents. The patent’s chemical complexity may create practical manufacturing barriers, particularly around stereochemical control and preparation of the fused triazolopyrazine core. Those barriers are operational rather than rights granted by the claims. How strong is the patent estate?The patent has a mixed strength profile. Strength factors
Exposure factors
Overall, claim 13 is the strongest asset for a product containing the named R-enantiomer. Claims 1 and 14 provide meaningful perimeter protection but carry greater validity, construction and enablement exposure. How does this patent compare with fezolinetant?Fezolinetant, marketed as Veoza by Astellas, is an FDA-approved nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause. It is an NK3-receptor antagonist and is commercially distinct from the Bayer elinzanetant program, which has been developed as a dual NK1/NK3 antagonist candidate [2][3].
The two programs may compete clinically but are not shown by the supplied claims to share the same active ingredient or patent scope. Patent overlap cannot be inferred from therapeutic class or receptor target alone. What licensing deals affect the patent?No licensing or acquisition transaction affecting U.S. Patent 9,987,274 is identified in the cited sources. The publicly associated development program has been advanced by Bayer. No third-party licensee is identified for the patent itself. A transaction involving the drug candidate, a patent family or regional commercialization rights would not necessarily appear in the patent document. Patent ownership, exclusive licensing and commercial collaboration status should therefore be distinguished when assessing control of the estate. What geographic coverage does the patent provide?U.S. Patent 9,987,274 provides rights only in the United States. Foreign protection would require separate national or regional patents derived from the applicable international or priority filings. Potentially relevant jurisdictions include:
The existence, scope, status and expiry of corresponding foreign patents cannot be assumed from the U.S. grant. A multinational launch assessment must treat each national family member separately. Key Takeaways
FAQs About U.S. Patent 9,987,274Is U.S. Patent 9,987,274 a composition-of-matter patent?No. The supplied claims are directed to methods of treating or preventing hot flashes using defined compounds. The patent does not independently claim the compounds as compositions. Does the patent cover both elinzanetant and its racemate?The broad claims expressly include the R-enantiomer or racemate. The exact answer for a commercial product depends on whether its structure matches the claimed Formula I genus or one of the named compounds. Can a generic avoid the patent by using the S-enantiomer?Possibly, but not automatically. The S-enantiomer is outside the literal scope of a claim limited to the R-enantiomer, while broader claims may separately cover a racemate or structurally defined genus. Does an approved product automatically receive Orange Book protection from this patent?No. FDA listing depends on whether the patent qualifies for listing and claims the approved drug or an approved method of use. Approval alone does not guarantee listing. Could a reformulated product avoid infringement?A different formulation may avoid a formulation patent, but it will not avoid a method claim if the product contains a claimed compound and is used for the patented hot-flash indication. References
More… ↓ |
Drugs Protected by US Patent 9,987,274
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | VEOZAH | fezolinetant | TABLET;ORAL | 216578-001 | May 12, 2023 | RX | Yes | Yes | 9,987,274 | ⤷ Start Trial | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,987,274
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2948455 | ⤷ Start Trial | 301272 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2948455 | ⤷ Start Trial | CA 2024 00017 | Denmark | ⤷ Start Trial |
| European Patent Office | 2948455 | ⤷ Start Trial | CR 2024 00017 | Denmark | ⤷ Start Trial |
| European Patent Office | 2948455 | ⤷ Start Trial | PA2024513 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2948455 | ⤷ Start Trial | LUC00342 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2948455 | ⤷ Start Trial | 2024C/523 | Belgium | ⤷ Start Trial |
| European Patent Office | 2948455 | ⤷ Start Trial | 122024000025 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
